

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

This Information Disclosure Statement accompanies the new patent application submitted herewith of the following Inventors: Magid A. ABOU-GHARBIA; James E. BARRETT; Wayne E. CHILDERS, Jr.; John A. MOYER

For: Methods for the Treatment and Prevention of Neurodegenerative Conditions.

1. Preliminary Statements

In accordance with 37 CFR 1.97 and 1.98, Applicants submit herewith patents, publications, or other information of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR 1.56. This Information Disclosure Statement is not to be construed as a representation that: (i) a search has been made; (ii) the information is material to the examination of this application; (iii) additional information material to the examination of this application does not exist; (iv) the information, protocols, results and the like reported by third parties are accurate or enabling; or (v) the information constitutes prior art to the subject invention.

2. ☒ Previously Cited Information

No copy of the patents, publications or other information cited on the attached form PTO-1449 is enclosed because it has been previously cited by or submitted to the Office in a prior application which is relied upon for an earlier filing date under 35 USC 120. Prior application is Application Number 09/711,793 filed on November 10, 2000 for Methods for the Treatment and Prevention of Neurodegenerative Conditions.

CERTIFICATE OF MAILING 37 CFR §1.10

I hereby certify that this paper and the documents referred to as enclosed therein are being deposited with the United States Postal Service on the date written below in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number EU947816065 addressed to the Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450.

Date

12-2-03

John R. Barker

3. ☐ Newly Cited Information
A legible copy of the patents, publications or other information cited on the attached form PTO-1449 is enclosed, except that no copy of a pending U.S. application, a U.S. patent, or a U.S. patent application publication is enclosed.
4. ☐ Concise Explanation
Documents cited above which are not in the English Language
- a. ☐ have been explained in the specification.
 - b. ☐ have an abstract (or other concise explanation) in English enclosed or, if readily available, a translation into English of the document is enclosed.
5. Form PTO-1449 is enclosed in duplicate.
6. Customer Number 25291.



Rebecca R. Barrett
December 2, 2003
Attorney for Applicants
Reg. No. 35,152

Wyeth
Patent Law Department
Five Giralda Farms
Madison, NJ 07940
Tel. No. (484) 865-8607

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	Not yet assigned
				Filing Date	December 2, 2003
				First Named Inventor	Magid A. Abou-Gharbia
				Group Art Unit	1617
Examiner Name	R. Travers				
Sheet	1	of	1	Attorney Docket Number	AM100146 C2

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number (If known)	Kind Code (If Known)			
	1.	5,380,725		M. Abou-Gharbia et al.	01-10-1995	
	2.	5,441,961		M.L. Cohen et al.	08-15-1995	
	3.	5,482,940		M. Abou-Gharbia et al.	01-09-1996	
	4.	5,691,324		Renven Sandyk	11-25-1997	
	5.	5,739,146		M.L. Cohen et al.	04-14-1998	
	6.	5,877,173		J.W. Olney et al.	03-02-1999	
	7.	5,902,815		J.W. Olney et al.	05-11-1999	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (If Known)				
	8.	DE	4 138 756		Kerstin Bode-Greuel	05-27-1993		<input type="checkbox"/>

OTHER PRIOR ART — NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		T
	9.	W. HOLT, Neuroprotection in CNS Diseases, 1997, 87-119, Marcel Dekker, Inc., NY		<input type="checkbox"/>
	10.	B. ENGELSEN, Neurotoxicity of Excitatory Amino-Acids, 1990, 311-332, Raven Press, NY		<input type="checkbox"/>
	11.	INCE et al., Rev. Contemp. Pharmacother., 1997, 195-212, 8		<input type="checkbox"/>
	12.	B. MELDRUM et al., Prog. Brain Res., 1998, 441-458		<input type="checkbox"/>
	13.	KOROSHETZ et al., Sci., 1996, 227-233, 17		<input type="checkbox"/>
	14.	C.D.R. DUNN, Scrips Reports, 1995, 61-90 and 149-159, PJB Publications, Richmond		<input type="checkbox"/>
	15.	J.E. ARROWSMITH et al., Stroke, 1998, 2357-2362, 29		<input type="checkbox"/>
	16.	J. DeVRY, Psychopharmacology, 1995, 1-26, 121		<input type="checkbox"/>
	17.	S. MATSUYAMA, Brain Res., 1996, 175-180, 728		<input type="checkbox"/>
	18.	J. DeVRY, Drugs of the Future, 1997, 341-349, 22		<input type="checkbox"/>
	19.	BODE-GREUEL, Pharm. of Cerebral Ischemia, 1990, 485-491		<input type="checkbox"/>
	20.	B. LIN et al., Stroke, 1990, 1734-1739, 21		<input type="checkbox"/>
	21.	H. NAKAYUAMA et al., Neurology, 1989, 1667-1673, 38		<input type="checkbox"/>
	22.	J. KRIEGLSTEIN et al., Eur. Neurology, 1989, 224-228, 29		<input type="checkbox"/>
	23.	H. FUJIKURA et al., Brain Res., 1989, 387-390, 494		<input type="checkbox"/>
	24.	COYLE, Harvard Rev. Psychiatry, 1996, 241-253, 3(5)		<input type="checkbox"/>
	25.	SMITH et al., Pharmacol. Biochem. Behavior, 1986, 1513-1519, 24		<input type="checkbox"/>
	26.	LAZARENO et al., Br. J. Pharmacol., 1993, 1120-27, 109		<input type="checkbox"/>
	27.	LUCKI et al., J. Pharma. and Exp. Ther., 1983, 133-39, 228(1)		<input type="checkbox"/>
	28.	DJALI et al., Soc. for Neuroscience Abs., 2000, 857.9, 26(1-2)		<input type="checkbox"/>
	29.	J. MOYER et al., Soc. for Neuroscience Abs., 1991, 1603, 17(1-2)		<input type="checkbox"/>
	30.	Drugs of the Future, Abs., 1992, Wy 50324, 17(11)		<input type="checkbox"/>
	31.	Mark S. KLEVEN et al., J. Pharmacol. Exp. Ther., 1996, 388-97, 276(2)		<input type="checkbox"/>
	32.	M. ABOU-GHARBIA et al., J. Med. Chem., 1999, 5077-5094, 42		<input type="checkbox"/>
	33.	G.W. BIELENBERG et al., Eur. J. Pharmacol., 1990, 1953-54, 183		<input type="checkbox"/>

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.